In addition, Ong et al. demonstrated that high expression of CD133 is associated with resistance of CSCs to 5-FU-based chemotherapy as well as with a significant worse survival in a colon cancer model [49]. The gene discussed is PROM1; the disease is malignant colon neoplasm.